Page 7 - Pre Funded Warrant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

KWESST Micro Systems (KWE) Announces Closing of United States Public Offering

KWESST Micro Systems (KWE) Announces Closing of United States Public Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesExchange commissionNewsfile corpProspectus departmentSystems incPre funded warrantPre funded warrants

Ascent Solar Technologies (ASTI) Files for $6M Share and Warrant Offering

Ascent Solar Technologies (ASTI) Files for $6M Share and Warrant Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ascent solar technologiesNasdaq capital marketPre funded warrantPre funded warrants

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative thera.

United statesKlinische einheitJustine omalleyProtara therapeutics incExchange commissionGuggenheim securitiesCompany contactOppenheimer coPre funded warrantsCommon warrantsCommon warrantPre funded warrantAcorn bioventuresBoxer capitalWoodline partnersCatalio capital management

Protara Therapeutics (TARA) Announces $45M Private Placement at $4 15/sh

Protara Therapeutics (TARA) Announces $45M Private Placement at $4 15/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGuggenheim securitiesOppenheimer coProtara therapeutics incProtara therapeuticsPre funded warrantsCommon warrantsCommon warrantPre funded warrantAcorn bioventuresBoxer capitalWoodline partnersCatalio capital managementStempoint capitalArmistice capitalVelan capital

Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity

Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TARA-002 program, the company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations. Data were derived from three-month evaluable NMIBC patients with CIS pooled across the company’s ADVANCED-1 Phase 1a, Phase 1b-expansio

Protara therapeutics incNon muscle invasive bladder cancerBacillus calmette guProtara therapeuticsCommon warrantPre funded warrantStock market gameBenzinga proDay trialVia equityBladder cancerProtara therapeuticsEvaluable patientsBacillus calmette guérinCholine chloride